Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world prevalence and prognostic significance of hepatotoxicity after chimeric antigen receptor T-cell therapy.

British journal of haematology·2026
Same author

Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Nature medicine·2026
Same author

Transitioning CAR-T therapy for multiple myeloma to the outpatient setting: First clinical insights with cilta-cel in Germany.

HemaSphere·2026
Same author

Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell Transplantation.

American journal of hematology·2026
Same author

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Nature medicine·2026
Same author

Integrated transcriptomic and TCR profiling reveals local immune dysregulation of T cells in Gl aGvHD.

Bone marrow transplantation·2026

Related Experiment Video

Updated: Sep 16, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Sequential BCMA CAR T-cell therapy in refractory multiple myeloma.

Tim Richardson1, Udo Holtick1, Jan Hendrik Frenking2

  • 1Department of Internal Medicine I, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Blood Advances
|July 11, 2025
PubMed
Summary

Sequential chimeric antigen receptor T-cell (CAR-T) therapy using two different BCMA-targeted products is safe and effective for relapsed multiple myeloma (MM). Prolonged response to initial CAR-T predicts durable outcomes with a second CAR-T infusion.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

811

Related Experiment Videos

Last Updated: Sep 16, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

811

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematology

Background:

  • Multiple myeloma (MM) relapse after BCMA-directed CAR-T therapy presents a significant clinical challenge.
  • Limited data exist on the efficacy and safety of re-administering CAR-T targeting the same antigen.

Purpose of the Study:

  • To evaluate the safety and efficacy of sequential BCMA-directed CAR-T therapy in heavily pretreated MM patients.
  • To identify predictors of response to second CAR-T infusion.

Main Methods:

  • Real-world analysis of 10 MM patients receiving ide-cel followed by cilta-cel (second CAR-T infusion) at three medical centers.
  • Bridging treatments were permitted between CAR-T therapies.
  • Assessment of safety, response rates, and progression-free survival.

Main Results:

  • Sequential BCMA-directed CAR-T therapy was safe, with no increased toxicity.
  • Achieved 100% very good partial response (VGPR) rate, with 60% achieving MRD-negativity.
  • Estimated 6-month progression-free survival was 64.8%.
  • Duration of response to the first CAR-T therapy predicted durable responses to the second CAR-T product.
  • BCMA antigen loss was infrequent.

Conclusions:

  • Sequential administration of two distinct BCMA-directed CAR-T products is feasible and effective in MM.
  • This approach offers a viable treatment option for patients relapsing after initial CAR-T therapy.
  • Prolonged response to first-line CAR-T therapy is a key factor for sustained benefit from sequential CAR-T treatment.